Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML

Bone Marrow Transplantation
C F Craddock

Abstract

Allogeneic stem cell transplantation represents the most active form of anti-leukaemic therapy in acute myeloid leukaemia (AML). Advances in transplant technology and supportive care have resulted in improved outcomes in patients allografted using a myeloablative conditioning regimen. At the same time the use of reduced-intensity conditioning regimens has allowed an immunologically mediated graft-versus-leukaemia effect to be exploited in older patients who were previously ineligible for transplantation on the grounds of age or comorbidity. This coupled with the increased availability of alternative stem cell sources, in the form of either unrelated or cord blood donations, has established allogeneic transplantation as a key therapeutic strategy in the treatment of both younger and older adults with AML.

References

Jun 18, 1981·The New England Journal of Medicine·P L WeidenUNKNOWN Seattle Marrow Transplant Team
Jul 26, 2002·British Journal of Haematology·Alan K BurnettUNKNOWN Medical Research Council Adult and Paediatric Working Parties
Oct 18, 2002·Blood·José A Pérez-SimónUNKNOWN Spanish and United Kingdom Collaborative Groups for Nonmyeloablative Transplantation
Nov 27, 2002·Proceedings of the National Academy of Sciences of the United States of America·Monica L GuzmanCraig T Jordan
Apr 17, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hartmut BertzJürgen Finke
Aug 14, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D C TaussigM J Barnett
Dec 17, 2003·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·H C FungS J Forman
Apr 16, 2004·The New England Journal of Medicine·Peter J M ValkRuud Delwel
May 5, 2005·Blood·Martin S TallmanJacob M Rowe
Jul 13, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Koen van BesienW Stock
Sep 13, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stefan FröhlingRoss L Levine

❮ Previous
Next ❯

Citations

Mar 13, 2010·Laboratory Hematology : Official Publication of the International Society for Laboratory Hematology·E RettingerP Lang
Jul 28, 2012·Stem Cell Reviews and Reports·S Abdul Wahid Fadilah, Md Pazil Aqilah
Jun 10, 2009·Expert Opinion on Drug Safety·Ulrike BacherAxel Rolf Zander
Jan 8, 2016·Leukemia Research·Li ZhouXiao-Tong Song
Sep 20, 2011·Best Practice & Research. Clinical Haematology·Mauro Di IanniMassimo F Martelli
Sep 1, 2009·Clinical Lymphoma & Myeloma·Stefan O CiureaMarcos de Lima
Mar 31, 2009·Hematology/oncology Clinics of North America·Allison M Green, Gary M Kupfer
Aug 21, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Hugo SousaRui Medeiros
Nov 13, 2008·Transplant Infectious Disease : an Official Journal of the Transplantation Society·T ShimaK Akashi
Feb 11, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Barbara DeschlerJürgen Finke
Aug 5, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Olle RingdénVanderson Rocha
Aug 29, 2013·The Neurohospitalist·Amy A PruittMyrna R Rosenfeld
Oct 27, 2009·Bone Marrow Transplantation·B N SavaniK Rezvani
Jun 24, 2017·Frontiers in Immunology·Anne M DickinsonHans Jochem-Kolb

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.